Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 45 clinical trials
High Dose Ritonavir/Lopinavir Liquid Formulation in Salvage Therapy for Protease Inhibitor Resistant HIV Disease

The purpose of this study is to evaluate the safety, tolerability and efficacy of higher doses of lopinavir/ritonavir, in combination with other anti-HIV medications when administered as

lopinavir
lopinavir/ritonavir
drug test
ritonavir
kaletra
  • 9 views
  • 07 Nov, 2020
  • 1 location
Switching From Protease Inhibitor/Ritonavir to Generic Single Tablet Regimen of Tenofovir Alafenamide/Emtricitibine/Dolutegravir

This is a phase III, multicenter, open-label, single-arm study of 190 virologically suppressed HIV-infected adults

protease
emtricitabine
HIV Vaccine
ritonavir
dolutegravir
  • 0 views
  • 26 Jan, 2021
  • 2 locations
Fight COVID-19 Trial

day and Ritonavir 200 mg ( or 2.5 mg/kg ) per day plus Oseltamivir 300 mg ( or 4-6 mg /kg ) per day versus Combination of Darunavir 400 mg every 8 hours plus ritonavir 200 mg (or 2.5 mg/kg ) per day

covid-19
oseltamivir
hydroxychloroquine
favipiravir
  • 0 views
  • 19 Mar, 2021
  • 1 location
Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Patients Starting Treatment With Anti-Hepatitis C Virus (HCV) Therapy

+ ritonavir in HIV/HCV coinfected patients. Secondary objective is to assess if Lpv/r monotherapy during HCV-treatment is associated with HIV efficacy versus optimized HAART.

haart
lopinavir/ritonavir
antiretroviral therapy
antiretroviral agents
lopinavir
  • 13 views
  • 07 Nov, 2020
  • 1 location
Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P

An open label, multicentre, international pilot study of paritaprevir/ritonavir, ombitasvir, dasabuvir with or without ribavirin or glecaprevir/pibrentasvir for people with recently acquired

  • 15 views
  • 02 Jul, 2021
  • 11 locations
Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy

Open-label prospective intensive pharmacokinetic study of dihydroartemisinin-piperaquine (DP) in HIV-infected children on efavirenz (EFV)-, lopinavir/ritonavir (LPV/r)-, or dolutegravir (DTG

  • 0 views
  • 27 Jan, 2021
  • 2 locations
Ivermectin vs Combined Hydroxychloroquine and Antiretroviral Drugs (ART) Among Asymptomatic COVID-19 Infection

This is an open label randomised controlled study of oral ivermectin (600 mcg/kg/d* 3 day) versus combined of hydroxychloroquine plus darunavir/ ritonavir for 5 days treatment among asymptomatic

  • 0 views
  • 27 Jan, 2021
  • 4 locations
Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)

. Moreover three substudies have been integrated. Currently, patients will be randomized to receive (hydroxy-)chloroquine (Treatment stopped after reports of safety issues), lopinavir/ritonavir, remdesivir

SARS
lopinavir/ritonavir
antiviral drugs
angiotensin
chloroquine
  • 0 views
  • 09 Mar, 2021
  • 9 locations
FLARE: Favipiravir +/- Lopinavir: A RCT of Early Antivirals

early antiviral therapy with either favipiravir + Lopinavir/ritonavir (LPV/r), LPV/r or favipiravir is associated with a decrease in viral load compared with placebo. The hypothesis is that this holds

SARS
fever
lopinavir/ritonavir
antiviral drugs
myalgia
  • 0 views
  • 08 May, 2021
  • 2 locations
Body Composition Sub-study of the D2EFT Trial

This is a non-randomised, controlled, parallel group, sub-study of D2EFT (NCT03017872), a randomised, open-label study in approximately 1,000 HIV-infected adults failing first-line antiretroviral therapy (ART) in low-middle income countries. The sub-study will be offered to all D2EFT sites with access to DXA technology for whole-body composition analysis. Sites will offer …

antiretroviral therapy
emtricitabine
antiretroviral agents
darunavir
ritonavir
  • 1 views
  • 23 Jan, 2021
  • 1 location